These issues limit the choice of methods suitable to robustly detect both germline and somatic BRCA1/2 variants in tumor‐derived DNA, with next‐generation sequencing (NGS) currently being the best available option to conduct full gene screening. This evidence concerns the gene BRCA1 and neoplasm.